Pozanicline

Drug Profile

Pozanicline

Alternative Names: A-87089.0; ABT-089

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Neuroprotectants; Nootropics; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Anxiety disorders; Attention-deficit hyperactivity disorder; Schizophrenia

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
  • 21 Oct 2009 Pharmacodynamics data from a preclinical study in ADHD presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 19 Nov 2008 Pharmacodynamics data from preclinical studies in ADHD and Alzheimer's disease and Cognition Disorders presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008) ,,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top